608 related articles for article (PubMed ID: 18064718)
21. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system.
Koch PE; Guo ZS; Kagawa S; Gu J; Roth JA; Fang B
Mol Ther; 2001 Mar; 3(3):278-83. PubMed ID: 11273768
[TBL] [Abstract][Full Text] [Related]
22. Muscle creatine kinase/SV40 hybrid promoter for muscle-targeted long-term transgene expression.
Takeshita F; Takase K; Tozuka M; Saha S; Okuda K; Ishii N; Sasaki S
Int J Mol Med; 2007 Feb; 19(2):309-15. PubMed ID: 17203206
[TBL] [Abstract][Full Text] [Related]
23. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle.
Brooks AR; Harkins RN; Wang P; Qian HS; Liu P; Rubanyi GM
J Gene Med; 2004 Apr; 6(4):395-404. PubMed ID: 15079814
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver.
Al-Dosari M; Zhang G; Knapp JE; Liu D
Biochem Biophys Res Commun; 2006 Jan; 339(2):673-8. PubMed ID: 16316630
[TBL] [Abstract][Full Text] [Related]
25. TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection.
Yao X; Yoshioka Y; Eto Y; Morishige T; Okada Y; Mizuguchi H; Mukai Y; Okada N; Nakagawa S
Biochem Biophys Res Commun; 2007 Oct; 362(2):419-24. PubMed ID: 17707336
[TBL] [Abstract][Full Text] [Related]
26. Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo.
Schowalter DB; Tubb JC; Liu M; Wilson CB; Kay MA
Gene Ther; 1997 Apr; 4(4):351-60. PubMed ID: 9176522
[TBL] [Abstract][Full Text] [Related]
27. Femoral intra-arterial injection: a tool to deliver and assess recombinant AAV constructs in rodents whole hind limb.
Gonin P; Arandel L; Van Wittenberghe L; Marais T; Perez N; Danos O
J Gene Med; 2005 Jun; 7(6):782-91. PubMed ID: 15693034
[TBL] [Abstract][Full Text] [Related]
28. Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area.
Kügler S; Kilic E; Bähr M
Gene Ther; 2003 Feb; 10(4):337-47. PubMed ID: 12595892
[TBL] [Abstract][Full Text] [Related]
29. Hepatocyte-specific gene expression from integrated lentiviral vectors.
Nash KL; Jamil B; Maguire AJ; Alexander GJ; Lever AM
J Gene Med; 2004 Sep; 6(9):974-83. PubMed ID: 15352070
[TBL] [Abstract][Full Text] [Related]
30. Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters.
Pluta K; Luce MJ; Bao L; Agha-Mohammadi S; Reiser J
J Gene Med; 2005 Jun; 7(6):803-17. PubMed ID: 15655804
[TBL] [Abstract][Full Text] [Related]
31. Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors.
Lohr F; Huang Q; Hu K; Dewhirst MW; Li CY
Clin Cancer Res; 2001 Nov; 7(11):3625-8. PubMed ID: 11705885
[TBL] [Abstract][Full Text] [Related]
32. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice.
Petry H; Brooks A; Orme A; Wang P; Liu P; Xie J; Kretschmer P; Qian HS; Hermiston TW; Harkins RN
Gene Ther; 2008 Jan; 15(1):54-60. PubMed ID: 17960164
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological expression in rat hepatocytes of a gene transferred by an adenovirus vector enabled by a chimeric promoter containing multiple cyclic adenosine monophosphate response elements.
Suzuki M; Singh RN; Crystal RG
Hepatology; 1998 Jan; 27(1):160-5. PubMed ID: 9425932
[TBL] [Abstract][Full Text] [Related]
34. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.
Jayan GC; Cordelier P; Patel C; BouHamdan M; Johnson RP; Lisziewicz J; Pomerantz RJ; Strayer DS
Gene Ther; 2001 Jul; 8(13):1033-42. PubMed ID: 11438838
[TBL] [Abstract][Full Text] [Related]
35. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors.
Kraaij R; van der Weel L; de Ridder CM; van der Korput HA; Zweistra JL; van Rijswijk AL; Bangma CH; Trapman J
Prostate; 2007 Jun; 67(8):829-39. PubMed ID: 17394196
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Tet-on system to avoid transgene down-regulation in ex vivo gene transfer to the CNS.
Johansen J; Rosenblad C; Andsberg K; Møller A; Lundberg C; Björlund A; Johansen TE
Gene Ther; 2002 Oct; 9(19):1291-301. PubMed ID: 12224012
[TBL] [Abstract][Full Text] [Related]
37. Activator protein 1-mediated transcriptional regulation strategy sustains long-term expression of a xenogeneic gene product in vivo: an implication for gene therapy targeting congenital protein deficiencies.
Sasaki S; Smith JM; Takase K; Okuda K; Ishii N; Takeshita F
Int J Mol Med; 2006 Aug; 18(2):289-97. PubMed ID: 16820937
[TBL] [Abstract][Full Text] [Related]
38. Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations.
Magnusson T; Haase R; Schleef M; Wagner E; Ogris M
J Gene Med; 2011 Jul; 13(7-8):382-91. PubMed ID: 21721074
[TBL] [Abstract][Full Text] [Related]
39. Promoter strength in adenovirus transducing vectors: down-regulation of the adenovirus E1A promoter in 293 cells facilitates vector construction.
Schaack J; Allen B; Orlicky DJ; Bennett ML; Maxwell IH; Smith RL
Virology; 2001 Dec; 291(1):101-9. PubMed ID: 11878880
[TBL] [Abstract][Full Text] [Related]
40. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy.
Moffatt S; Hays J; HogenEsch H; Mittal SK
Virology; 2000 Jun; 272(1):159-67. PubMed ID: 10873758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
